Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jason K. Sicklick"'
Autor:
Sunil J. Advani, Hyunho Yoon, Rowan Ustoy, Mayra Yebra, Vipul R. Sheth, Sudeep Banerjee, Michael Heinrich, Christian M. Metallo, Joseph A. Aguilera, Sangkyu Noh, Scott M. Lippman, Razelle Kurzrock, Chih-Min Tang, Olivier Harismendy, Paul T. Fanta, Adam M. Burgoyne, Avi Kumar, Thekla Cordes, Shruti Bhargava, Sam Li, Jason K. Sicklick, Christopher L. Corless
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract, with mutant succinate dehydrogenase (SDH) subunits (A–D) comprising less than 7.5% (i.e., 150–200/year) of new cases annually in the United S
Autor:
Ryosuke Okamura, Razelle Kurzrock, Justin Shaya, Jason K. Sicklick, Rebecca E. Jimenez, Shumei Kato, Jacob J. Adashek, Suzanna Lee
Publikováno v:
Clinical Cancer Research. 27:2792-2797
Purpose: Cyclin and MAPK/MEK-related gene alterations are implicated in cell-cycle progression and cancer growth. Yet, monotherapy to target the cyclin (CDK4/6) or the MEK pathway has often yielded disappointing results. Because coalterations in cycl
Publikováno v:
Eur J Cancer
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials. This reanalysis dramatically decreases response rates in precision
Autor:
Jayanth S. Shankara Narayanan, Hyunho Yoon, Rebekah R. White, Mayra Yebra, Sudeep Banerjee, Partha Ray, Jason K. Sicklick, Chih-Min Tang, Mara Gilardi
Publikováno v:
Mol Cancer Ther
Gastrointestinal stromal tumor (GIST), the most common sarcoma, is characterized by KIT protein overexpression, and tumors are frequently driven by oncogenic KIT mutations. Targeted inhibition of KIT revolutionized GIST therapy and ushered in the era
Autor:
Kevin Porras, Mayra Yerba, Paul T. Fanta, Jason K. Sicklick, Pushpa Neppala, Adam M. Burgoyne, Sudeep Banerjee
Publikováno v:
Cancer Metastasis Rev
Gastrointestinal stromal tumors (GISTs) are increasingly recognized as having diverse biology. With the development of tyrosine kinase inhibitors molecularly matched to oncogenic KIT and PDGFRA mutations, GISTs have become a quintessential model for
Autor:
Pradip De, J. Jack Lee, Michael E. Hahn, Shumei Kato, Hitendra Patel, Jason K. Sicklick, Brian Leyland-Jones, Jessica Guido, Benjamin M. Solomon, Mina Nikanjam, Scott M. Lippman, Paul T. Fanta, Casey Williams, Sarah Boles, Rana R. McKay, Razelle Kurzrock, Jeffrey S. Ross, Ryosuke Okamura, Amy Krie
Publikováno v:
Genome Medicine
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Background Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and
Publikováno v:
ACS sensors, vol 6, iss 5
ACS Sens
ACS Sens
An electrochemical sensor based on a conformation-changing aptamer is reported to detect soluble KIT, a cancer biomarker, in human serum. The sensor was fabricated with a ferrocene-labeled aptamer (Kd < 5 nM) conjugated to a gold electrode. Quantitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784db20bb54add0e19f25da41483fb8d
https://escholarship.org/uc/item/17v616zh
https://escholarship.org/uc/item/17v616zh
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Autor:
Ryosuke Okamura, Razelle Kurzrock, J. Jack Lee, Philip J. Stephens, Michael E. Hahn, Shumei Kato, Amy Krie, Jennifer Webster, Jeffrey S. Ross, Brian Leyland-Jones, David Piccioni, Pradip De, Scott M. Lippman, Maria Schwaederle, Adam Benson, Paul T. Fanta, Vincent A. Miller, Jason K. Sicklick, Casey Williams
Publikováno v:
Nature medicine, vol 25, iss 5
Nature medicine
Nature medicine
Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed outcomes for some malignancies.1 Tumor complexity and heterogeneity suggest that the “precision medicine” par
Autor:
Noor Khalid, Razelle Kurzrock, Jacob J. Adashek, Suzanna Lee, Shumei Kato, Jason K. Sicklick, Van Thomas Nguyen, Ryosuke Okamura
Publikováno v:
JCI insight, vol 6, iss 1
JCI Insight, Vol 6, Iss 1 (2021)
JCI Insight
JCI Insight, Vol 6, Iss 1 (2021)
JCI Insight
BACKGROUND Although CDK4/6 inhibitors are an established treatment for hormone receptor–positive, HER2-negative metastatic breast cancers, their benefit in other malignancies remains limited.METHODS We investigated factors associated with clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66de530f4ac6efbc82971e89d868547b
https://escholarship.org/uc/item/66p2z8d2
https://escholarship.org/uc/item/66p2z8d2
Autor:
Sudeep, Banerjee, Hyunho, Yoon, Stephanie, Ting, Chih-Min, Tang, Mayra, Yebra, Alexander T, Wenzel, Huwate, Yeerna, Jill P, Mesirov, Robert J, Wechsler-Reya, Pablo, Tamayo, Jason K, Sicklick
Publikováno v:
Mol Cancer Ther
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib, a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST and adjuvant therapy only delays recurrence in high-risk